glp-1 discontinuation rates Treatment among users of receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes | Diabetologia New Truveta study highlights patterns

People using these medicines can lose more weight than with diet and exercise alone a loss of between 5% and 21% of their body weight can be expected depending on which medicine is taken and how long it is used

It raises the risk of type 2 diabetes, heart disease, sleep problems, and depression conditions that already shadow many people with ADHD

Among emerging anti-diabetic candidates, glucagon like peptide-1 (GLP-1) based therapies carry special cardiovascular implications, exerting both direct as well as indirect effects

Strive Compounding Pharmacy sues Eli Lilly and Novo Nordisk over alleged GLP-1 weight loss drug competition limits

elegans div-1 encodes the B subunit of the DNA polymerase alpha-primase complex and is highly expressed in proliferative germ cells